XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2024
USD ($)
Agreement
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]      
Revenue $ 119,497 $ 130,524  
AstraZeneca [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Number of collaboration agreements | Agreement 2    
Revenue $ 11,685 $ 24,425  
Deferred contract revenue $ 1,900   $ 0
AstraZeneca [Member] | Revenue [Member] | Strategic Partner [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Concentration percentage 10.00% 19.00%  
AstraZeneca [Member] | Maximum [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Cumulative payments received $ 910,000    
WAINUA [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Number of collaboration agreements | Agreement 1    
WAINUA [Member] | Maximum [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Next payment to be achieved $ 30,000    
Cardiovascular, Renal and Metabolic Diseases [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Number of collaboration agreements | Agreement 1